Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

BACKGROUND: Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2×2 factorial design to test two hypotheses: whether use of accelerated epirubicin would improve time to tumour recurrence (TTR); and whether use of oral capecitabine instea...

Descripción completa

Detalles Bibliográficos
Autores principales: Cameron, David, Morden, James P, Canney, Peter, Velikova, Galina, Coleman, Robert, Bartlett, John, Agrawal, Rajiv, Banerji, Jane, Bertelli, Gianfilippo, Bloomfield, David, Brunt, A Murray, Earl, Helena, Ellis, Paul, Gaunt, Claire, Gillman, Alexa, Hearfield, Nicholas, Laing, Robert, Murray, Nicholas, Couper, Niki, Stein, Robert C, Verrill, Mark, Wardley, Andrew, Barrett-Lee, Peter, Bliss, Judith M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489700/
https://www.ncbi.nlm.nih.gov/pubmed/28600210
http://dx.doi.org/10.1016/S1470-2045(17)30404-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489700/
https://www.ncbi.nlm.nih.gov/pubmed/28600210
http://dx.doi.org/10.1016/S1470-2045(17)30404-7

Ejemplares similares